To research, develop and carry out clinical trials with monoclonal antibodies in order to offer patients new alternatives for cancer treatment that are more effective and have fewer side effects than those currently in existence.
To contribute to the reduction of the social and economic costs brought about by illness in the country. To make use of the technical and scientific competence existing in Brazil in order to innovate and export technology with major aggregated value.